Cvrx Inc (CVRX) Stock Price, Quote & News

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular sy...

Industry: Medical Devices

Sector: Healthcare

Phone: 763 416 2840

Fax: 763 416 2841

Website: www.cvrx.com

Address:

9201 West Broadway Avenue, Suite 650, Minneapolis, United States

commoncentsinvestor Jun. 23 at 1:51 PM

$CVRX Medical Breakthroughs: Barostim implant procedure to prevent heart failure KRGV TV Rio Grande Texas https://www.krgv.com/news/medical-breakthroughs-barostim-implant-procedure-to-prevent-heart-failure

1 · Reply

MedDevice Jun. 22 at 9:37 PM

$CVRX 16 revenue units at $31,500 asp gets CVRx to high end of guidance. With 6% pull through on Humana (20% MS x 33% payer mix), this is the floor. A guide up after being surprised (per ceo comments) seems like a no-brainer. Big report coming that could set the stage for a ton of positive momentum into the back half of the year.

0 · Reply

MedDevice Jun. 9 at 1:12 PM

$CVRX Humana NCD is a barometer for execution, and the CFO leaves 24 hours before the Goldman HC Conference? Timing is interesting to say the least, although no good time for the Chief Legal Counsel, Chief HR Officer and CFO to leave within 6 months of one another.

3 · Reply

newfguy Jun. 9 at 12:32 PM

$CVRX CFO leaving is bearish

1 · Reply

focafoca99 Jun. 9 at 12:13 PM

$CVRX indicated its CFO will resign and the company is searching for a successor.

0 · Reply

BuyOnRedSellOnGreen Jun. 9 at 11:37 AM

$CVRX CFO transition is a yellow flag, not a thesis-breaker imo. I don’t love the timing because this is still a cash-burning medtech with debt, ATM/dilution risk, and a long road to cash flow breakeven. That said, this looks orderly. CFO stays until successor is named and remains available as advisor through Feb 2027. No mention of accounting issues, restatements, disagreements, or internal control problems. Holding my starter. Not adding on this news.

0 · Reply

MITornado Jun. 8 at 3:07 PM

$CVRX I like the data… others do too. Momentum building into the end of the year is my guess.

0 · Reply

BuyOnRedSellOnGreen Jun. 4 at 8:12 PM

$CVRX when I show up good things happen

2 · Reply

Twister8 Jun. 4 at 4:00 PM

$CVRX Humana, who is next?

2 · Reply

BuyOnRedSellOnGreen Jun. 4 at 1:34 PM

$CVRX took a starter position this morning

0 · Reply

CVRx, Inc. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-09T11:41:42.000Z - 16 days ago

CVRx CFO Jared Oasheim to step down

Jun 9, 2026, 7:30 AM EDT - 16 days ago

CVRx Announces Chief Financial Officer Transition

Jun 2, 2026, 11:40 AM EDT - 22 days ago

CVRx, Inc. Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 11:40 AM EDT - 22 days ago

CVRx, Inc. Slides: 46th Annual William Blair Growth Stock Conference

Jun 1, 2026, 11:00 AM EDT - 23 days ago

CVRx, Inc. Transcript: AGM 2026

May 27, 2026, 4:30 PM EDT - 4 weeks ago

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026, 4:30 PM EDT - 5 weeks ago

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

2026-05-14T14:43:59.000Z - 5 weeks ago

CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy

HUM

May 14, 2026, 8:00 AM EDT - 6 weeks ago

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

May 11, 2026, 4:30 PM EDT - 6 weeks ago

CVRx, Inc. Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 6 weeks ago

CVRx, Inc. Earnings release: Q1 2026

May 11, 2026, 4:30 PM EDT - 6 weeks ago

CVRx, Inc. Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 6 weeks ago

CVRx Reports First Quarter 2026 Financial and Operating Results

2026-05-04T21:15:14.000Z - 7 weeks ago

CVRx enrolls first patient in BENEFIT-HF trial

May 4, 2026, 4:30 PM EDT - 7 weeks ago

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Apr 27, 2026, 4:30 PM EDT - 2 months ago

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

Apr 20, 2026, 4:30 PM EDT - 2 months ago

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

Apr 20, 2026, 8:00 AM EDT - 2 months ago

CVRx, Inc. Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

CVRx, Inc. Proxy statement: Proxy filing

Apr 9, 2026, 9:00 AM EDT - 2 months ago

CVRx, Inc. Investigated by the Portnoy Law Firm

Mar 2, 2026, 8:30 AM EST - 4 months ago

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

2026-02-13T12:10:44.000Z - 4 months ago

CVRx price target lowered to $6 from $7 at JPMorgan

2026-02-13T11:55:30.000Z - 4 months ago

CVRx price target lowered to $10 from $11 at Canaccord

Feb 12, 2026, 4:30 PM EST - 4 months ago

CVRx, Inc. Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 4 months ago

CVRx, Inc. Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 4 months ago

CVRx, Inc. Earnings release: Q4 2025

Jan 29, 2026, 4:10 PM EST - 5 months ago

CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

2026-01-22T21:20:25.000Z - 5 months ago

CVRx initiates BENEFIT-HF clinical trial

Jan 22, 2026, 4:05 PM EST - 5 months ago

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Jan 14, 2026, 6:45 PM EST - 5 months ago

CVRx, Inc. Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 5 months ago

CVRx, Inc. Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 5 months ago

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

2026-01-06T13:52:44.000Z - 6 months ago

CVRx announces implementation of new category I CPT codes for Barostim therapy

Jan 6, 2026, 8:30 AM EST - 6 months ago

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

Dec 22, 2025, 8:30 AM EST - 6 months ago

CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 2:00 PM EST - 7 months ago

CVRx, Inc. Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 8:30 AM EST - 7 months ago

CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 3:00 AM EST - 7 months ago

CVRx, Inc. Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:00 AM EST - 7 months ago

CVRx, Inc. Slides: FY 2025

2025-11-06T13:55:34.000Z - 8 months ago

CVRx files $150M mixed securities shelf

2025-11-06T13:51:58.000Z - 8 months ago

CVRx price target raised to $13 from $11 at Cantor Fitzgerald

2025-11-06T13:38:03.000Z - 8 months ago

CVRx price target raised to $11 from $9 at Canaccord

Nov 6, 2025, 7:00 AM EST - 8 months ago

CVRx, Inc. Registration statement: Registration Filing

Nov 5, 2025, 4:30 PM EST - 8 months ago

CVRx, Inc. Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

CVRx, Inc. Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 8 months ago

CVRx, Inc. Earnings release: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 8 months ago

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

Aug 12, 2025, 3:00 PM EDT - 11 months ago

CVRx, Inc. Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 3:00 PM EDT - 11 months ago

CVRx, Inc. Slides: Canaccord Genuity’s 45th Annual Growth Conference

Aug 4, 2025, 4:30 PM EDT - 11 months ago

CVRx, Inc. Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 11 months ago

CVRx, Inc. Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 11 months ago

CVRx, Inc. Earnings release: Q2 2025

Aug 4, 2025, 4:05 PM EDT - 11 months ago

CVRx Reports Second Quarter 2025 Financial and Operating Results

Jul 29, 2025, 8:30 AM EDT - 11 months ago

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 7:30 AM EDT - 1 year ago

CVRx Announces Positive News on Outpatient Payment for Barostim

Jun 4, 2025, 11:00 AM EDT - 1 year ago

CVRx, Inc. Transcript: 45th Annual William Blair Growth Stock Conference

Jun 4, 2025, 11:00 AM EDT - 1 year ago

CVRx, Inc. Slides: 45th Annual William Blair Growth Stock Conference

May 28, 2025, 4:30 PM EDT - 1 year ago

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

CVRx, Inc. Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings release: Q1 2025

Apr 24, 2025, 4:30 PM EDT - 1 year ago

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

CVRx, Inc. Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

CVRx, Inc. Proxy statement: Proxy Filing

Apr 7, 2025, 4:05 PM EDT - 1 year ago

CVRx Reports Preliminary First Quarter 2025 Financial Results

Feb 12, 2025, 2:45 PM EST - 1 year ago

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Feb 4, 2025, 4:30 PM EST - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q4 2024

Feb 4, 2025, 4:30 PM EST - 1 year ago

CVRx, Inc. Annual report: Q4 2024

Feb 4, 2025, 4:30 PM EST - 1 year ago

CVRx, Inc. Earnings release: Q4 2024

Feb 4, 2025, 4:05 PM EST - 1 year ago

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Jan 21, 2025, 4:30 PM EST - 1 year ago

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

CVRx, Inc. Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

CVRx, Inc. Slides: FY 2025

Dec 23, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 3:30 PM EST - 1 year ago

CVRx, Inc. Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Oct 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Quarterly report: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings release: Q3 2024

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim

Oct 15, 2024, 4:30 PM EDT - 1 year ago

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members

commoncentsinvestor Jun. 23 at 1:51 PM

1 · Reply

MedDevice Jun. 22 at 9:37 PM

0 · Reply

MedDevice Jun. 9 at 1:12 PM

3 · Reply

newfguy Jun. 9 at 12:32 PM

$CVRX CFO leaving is bearish

1 · Reply

focafoca99 Jun. 9 at 12:13 PM

$CVRX indicated its CFO will resign and the company is searching for a successor.

0 · Reply

BuyOnRedSellOnGreen Jun. 9 at 11:37 AM

0 · Reply

MITornado Jun. 8 at 3:07 PM

$CVRX I like the data… others do too. Momentum building into the end of the year is my guess.

0 · Reply

BuyOnRedSellOnGreen Jun. 4 at 8:12 PM

$CVRX when I show up good things happen

2 · Reply

Twister8 Jun. 4 at 4:00 PM

$CVRX Humana, who is next?

2 · Reply

BuyOnRedSellOnGreen Jun. 4 at 1:34 PM

$CVRX took a starter position this morning

0 · Reply

1111tu Jun. 3 at 8:49 PM

$CVRX another interesting comment made by Hykes is that they are considering going back to the FDA to seek label expansion based upon growing real world evidence.

0 · Reply

1111tu Jun. 3 at 8:25 PM

$CVRX traditional Medicare paid on 96% of claims

0 · Reply

1111tu Jun. 3 at 8:21 PM

$CVRX Hykes stated yesterday while speaking at the Wm Blair Conference that April Medicare Advantage approvals are now 60+%.

1 · Reply

commoncentsinvestor Jun. 3 at 6:25 PM

$CVRX WHAT Ai has to say about CVRX: AI Overview CVRx (NASDAQ: CVRX) is making major commercial and clinical strides with its Barostim heart failure device. The company recently reported strong Q1 2026 revenue of $\$14.8$ million (a 20% year-over-year increase) and announced that Humana will now cover Barostim for Medicare Advantage members.Here are the latest corporate, clinical, and financial updates:Commercial & Reimbursement UpdatesHumana Medicare Advantage Coverage: Effective May 1, 2026, Humana became the first major Medicare Advantage plan to issue a formal coverage policy for Barostim, securing access for its 5.2 million members.Category I CPT Codes: Permanent Category I CPT codes for the Barostim procedure officially went into effect on January 1, 2026, eliminating the predictability issues associated with previous The number of active medical centers actively implanting the Barostim device in the United States has grown to 257.

0 · Reply

MedDevice May. 26 at 1:49 AM

$CVRX Humana has around 17% Medicare Advantage National Market Share. Earnings rpt stated around 33% from MA plans. Additional 5% of eligible patients now bypass PA. Should flow through to the 30 day approval rate in short order.

1 · Reply

1111tu May. 22 at 3:03 PM

$CVRX Benefit-HF trial design paper published in Journal of Cardiac Failure. https://onlinejcf.com/article/S1071-9164(26)00249-6/fulltext

0 · Reply

1111tu May. 22 at 2:15 PM

$CVRX 5 Territory Manager openings + 4 Associate Territory Manager openings on their career page today.

0 · Reply

BuyOnRedSellOnGreen May. 22 at 2:09 PM

$CVRX should have bought instead of penny pinched

0 · Reply

Twister8 May. 20 at 3:42 PM

$CVRX Validation from Humana is a bet worth taking... loaded sub 6.

0 · Reply

Twister8 May. 20 at 2:40 PM

$CVRX anticipating more medicare advantage news from other carriers adopting barostim into their policy guidelines.

0 · Reply

Twister8 May. 15 at 1:21 AM

$CVRX One of the hurdles has been denials from Medicare advantage, Humana is a biggie

0 · Reply

Olivia_Strickland May. 14 at 7:06 PM

$CVRX +18% on 2.2x vol and the catalyst is a single insurer coverage policy headline that dropped this morning. nine times out of ten "Medicare Advantage coverage" prints get a 3% pop and a fade by lunch, but this one is acting different and the reason is buried in the policy details, not the press release. who's actually read the coverage criteria here, because the tape thinks it matters more than the headline suggests? full breakout structure on the chart: https://tapeboard.com/chart/CVRX?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=cvrx-bk-up-chart

1 · Reply

Market Cap	128.97M
Revenue (ttm)	56.65M
Net Income (ttm)	-53.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-94.10%
Debt to Equity Ratio	2.01

Volume	344,900
Avg Vol	324,412
Day's Range	N/A - N/A
Shares Out	26.54M
Stochastic %K	73%
Beta	0.80
Analysts	Strong Sell
Price Target	$11.17